Highlights from our Second Annual ESG Investor Event
Moderna’s commitment to Environmental, Social, and Governance (ESG) principles is not just a corporate mandate, it's a strategic framework that guides every facet of our operations. At our second ESG Investor Event, we highlighted the five key areas of our ESG strategy, reflecting a holistic approach to sustainability and corporate citizenship.
A Five-Pillar Approach to ESG
Our ESG strategy is built upon five foundational pillars, each addressing critical aspects of sustainability and ethical practice, and driven by a steadfast commitment to advance global health:
1. Medicines for Patients
Central to our mission is the desire to have a transformative impact on patients' lives. By harnessing the power of mRNA technology, we are developing therapies that address the global unmet medical needs of today and of the future. Our commitment to patient impact is also evident in our efforts to enhance the accessibility of our innovative therapies, and our strategic partnerships to benefit global health.
We are acutely aware of the environmental challenges facing our planet and their impact on human health. We are actively working to minimize our ecological footprint. We have set a goal for net-zero carbon emissions (Scopes 1 & 2) by 2030, a testament to our commitment to combating climate change. Initiatives include optimizing energy use, investing in renewable energy, and designing sustainable products and facilities.
3. Employees & Culture
We understand that our success is directly linked to the well-being and development of our employees. We invest in creating a diverse, equitable, and inclusive work environment where every employee can thrive. Professional growth, DEI initiatives, and a culture of collaboration and respect are the hallmarks of the Moderna employee experience.
Our role as a corporate citizen extends beyond the realm of biotechnology. We actively engage with communities, support educational initiatives, promote public health, and advocate for belonging, inclusion and diversity to drive positive social change. By leveraging our resources and expertise, we aim to build stronger, healthier communities around the world.
5. Governance & Ethics
Integrity and ethical conduct are non-negotiable, we adhere to the highest standards of business ethics, ensuring transparency and accountability in all our operations. Robust compliance frameworks and a zero-tolerance policy for unethical behavior reinforce our commitment to ethical governance.
Looking Forward: A Roadmap for ESG Excellence
The ESG Investor Event was not only a platform to review our accomplishments but also an opportunity to chart the course for future ESG endeavors. We are dedicated to continuous improvement across all five ESG pillars, ensuring that our business growth is aligned with the broader goals of societal and environmental well-being.
Our five-pillar ESG strategy is a blueprint for responsible and sustainable growth in the biotech industry, and our holistic approach to ESG demonstrates a deep understanding of the interconnectedness of our business with global health, the environment, and society at large. As we forge ahead, our commitment to these five areas will undoubtedly lead to meaningful progress and help us achieve our mission to deliver the greatest possible impact to people through mRNA medicines.
Forward Looking Statements
This blog contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding: Moderna's ability to leverage its mRNA platform to address global unmet medical needs of today and of the future; Moderna's commitment to achieving net-zero carbon emissions (Scopes 1 & 2) in its global operations by 2030; and Moderna’s dedication to continuous improvement across its five ESG pillars and resulting meaningful progress toward its mission. The forward-looking statements in this blog are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond Moderna's control and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements. These risks, uncertainties, and other factors include, among others, those risks and uncertainties described under the heading "Risk Factors" in Moderna's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (SEC), and in subsequent filings made by Moderna with the SEC, which are available on the SEC's website at www.sec.gov. Except as required by law, Moderna disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise. These forward-looking statements are based on Moderna's current expectations and speak only as of the date of this blog.